Wall Street analysts expect BIO-TECHNE Corp (NASDAQ:TECH) to announce $1.00 earnings per share for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for BIO-TECHNE’s earnings, with the lowest EPS estimate coming in at $0.90 and the highest estimate coming in at $1.14. BIO-TECHNE reported earnings per share of $1.02 during the same quarter last year, which indicates a negative year-over-year growth rate of 2%. The company is scheduled to report its next earnings report on Tuesday, February 5th.
According to Zacks, analysts expect that BIO-TECHNE will report full year earnings of $4.49 per share for the current year, with EPS estimates ranging from $4.39 to $4.75. For the next financial year, analysts expect that the firm will report earnings of $5.13 per share, with EPS estimates ranging from $4.88 to $5.27. Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for BIO-TECHNE.
BIO-TECHNE (NASDAQ:TECH) last posted its earnings results on Tuesday, October 30th. The biotechnology company reported $0.98 EPS for the quarter, topping analysts’ consensus estimates of $0.95 by $0.03. BIO-TECHNE had a net margin of 19.19% and a return on equity of 14.09%. The business had revenue of $163.00 million for the quarter, compared to analysts’ expectations of $162.34 million. During the same period in the previous year, the company posted $0.90 earnings per share. The business’s revenue for the quarter was up 12.7% compared to the same quarter last year.
TECH has been the topic of a number of recent research reports. Zacks Investment Research cut shares of BIO-TECHNE from a “hold” rating to a “strong sell” rating in a research report on Wednesday, August 15th. ValuEngine upgraded shares of BIO-TECHNE from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, September 11th. Argus lifted their price target on shares of BIO-TECHNE from $210.00 to $230.00 and gave the stock a “buy” rating in a research note on Tuesday, October 2nd. BidaskClub lowered shares of BIO-TECHNE from a “strong-buy” rating to a “buy” rating in a research note on Thursday, October 4th. Finally, Goldman Sachs Group initiated coverage on shares of BIO-TECHNE in a research note on Wednesday, October 17th. They issued a “neutral” rating and a $190.00 price target for the company. Four analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. BIO-TECHNE presently has an average rating of “Buy” and a consensus target price of $181.00.
Several large investors have recently modified their holdings of TECH. Bank of Montreal Can bought a new stake in shares of BIO-TECHNE in the second quarter worth $2,773,000. Janney Montgomery Scott LLC bought a new stake in BIO-TECHNE during the second quarter valued at $780,000. Aperio Group LLC increased its stake in BIO-TECHNE by 2.7% during the second quarter. Aperio Group LLC now owns 36,108 shares of the biotechnology company’s stock valued at $5,342,000 after purchasing an additional 934 shares during the last quarter. Commonwealth Equity Services LLC increased its stake in BIO-TECHNE by 161.4% during the second quarter. Commonwealth Equity Services LLC now owns 10,456 shares of the biotechnology company’s stock valued at $1,547,000 after purchasing an additional 6,456 shares during the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. bought a new stake in BIO-TECHNE during the second quarter valued at $231,000. Institutional investors and hedge funds own 93.90% of the company’s stock.
NASDAQ TECH opened at $156.22 on Wednesday. BIO-TECHNE has a 52 week low of $125.84 and a 52 week high of $206.04. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.50 and a current ratio of 4.59. The firm has a market cap of $6.06 billion, a PE ratio of 38.38, a PEG ratio of 2.83 and a beta of 1.05.
The business also recently declared a quarterly dividend, which was paid on Friday, November 23rd. Investors of record on Friday, November 9th were paid a $0.32 dividend. The ex-dividend date was Thursday, November 8th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.82%. BIO-TECHNE’s dividend payout ratio (DPR) is presently 31.45%.
BIO-TECHNE Company Profile
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates in three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers specialized proteins, such as cytokines and growth factors, immunoassays, antibodies, and related reagents to the biotechnology research community; and in situ hybridization, media, and other cell culture products and reagents.
Recommended Story: What factors cause inflation to rise?
Get a free copy of the Zacks research report on BIO-TECHNE (TECH)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BIO-TECHNE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIO-TECHNE and related companies with MarketBeat.com's FREE daily email newsletter.